AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results

    All amounts are in U.S. dollars

    QUEBEC CITY, Aug. 11 /CNW Telbec/ - AEterna Zentaris Inc. (NASDAQ:   AEZS,
TSX: AEZ) ("the Company"), a global biopharmaceutical company focused on
endocrinology and oncology, today reported financial and operating results as
at and for the three-month and six-month periods ended June 30, 2009.

    Second Quarter 2009 Highlights


    - Two poster presentations at the American Association of Cancer
      Research ("AACR") Annual Meeting on in vitro and in vivo results for
      AEZS-126 in human tumors, and one poster presentation on Phase 1
      results with AEZS-112 in solid tumors or lymphoma.

    - Notification from Nasdaq that the Company had regained compliance
      with Nasdaq's minimum bid price rules.


    - Presentation at the American Society of Clinical Oncology ("ASCO")
      Annual Meeting of results supporting evaluation of AEZS-108 in
      prostate cancer.


    - Presentation at the ASCO Annual Meeting of positive Phase 2 data on
      perifosine in advanced metastatic colon cancer and advanced renal cell
      carcinoma by the Company's partner, Keryx Biopharmaceuticals, Inc.

    - Acquisition from Ardana Bioscience Ltd. of all assets relating to

    - Disclosure of neutral results for the Company's Phase 2 trial in
      non-small cell lung cancer with perifosine as radioenhancer.

    - Announcement of the initiation of the extension of the Company's North
      American Phase 3 efficacy study with cetrorelix in benign prostatic
      hyperplasia ("BPH"). This extension of the study is sponsored by
      sanofi-aventis, the Company's partner for the US market.

    - Poster presentation at the Endocrine Society ("ENDO") Annual Meeting
      on AEZS-130 as a simple diagnostic test for adult growth hormone

    - Announcement that data from the Company's safety study of the Phase 3
      program in BPH with cetrorelix are expected to be disclosed ahead of
      schedule, from the fourth quarter 2009 to the third quarter of 2009.

    - Completion of a registered direct offering of US$10 million of units
      comprised of common shares and common share purchase warrants to
      certain institutional investors.

    Subsequent to Quarter-End


    - Publication in Proceedings of the National Academy of Sciences of new
      data supporting the use of the Company's ghrelin receptor antagonist
      compound, AEZS-123, for the treatment of alcohol dependence.


    - Keryx, the Company's partner and licensee for perifosine in the North
      American market, reached an agreement with the FDA regarding a Special
      Protocol Assessment on the design of a Phase 3 trial with perifosine
      in multiple myeloma.

    Juergen Engel, Ph.D., AEterna Zentaris President and Chief Executive
Officer, commented, "The quarter was marked by continued progress of our
current Phase 3 program in BPH with cetrorelix. As part of this same program
and with a sponsorship from sanofi-aventis, our partner for cetrorelix in the
US market, we initiated the extension of our North American efficacy study. We
also moved up disclosure of the safety trial results of this program ahead of
schedule, from Q4 to Q3 2009. Furthermore, we presented data on some of our
anticancer compounds at both the AACR and ASCO annual meetings, which
underlined the breadth and potential of our product pipeline. Also, we were
very pleased with Keryx's announcement that they expect to begin a Phase 3
trial with perifosine in multiple myeloma, following their recent SPA
agreement with the FDA. We now look forward to disclosing first results of our
Phase 3 program in BPH during the third quarter, as we continue to deploy all
the necessary efforts to bring cetrorelix to market."
    Dennis Turpin, the Company's Senior Vice President and Chief Financial
Officer, added, "We were pleased to complete a $10 million registered direct
offering during the quarter. This vote of confidence from institutional
investors provides us with additional funds that will be used mainly to
further strengthen our promising oncology pipeline."

    JUNE 30, 2009

    Consolidated revenues were $8.4 million for the three-month period ended
June 30, 2009, compared to $10.5 million for the same period in 2008. This
decrease is related to lower royalty revenues having been recognized in the
second quarter of 2009 in connection with the Company's agreement with Merck
Serono, where amortization of the proceeds received from Cowen for the
three-month period ended June 30, 2009 was lower than the royalty revenues
generated and payable directly by Merck Serono during the second quarter of
2008. The comparative decrease in sales and royalties is also attributable to
euro to US dollar exchange rate fluctuations, given the comparative
strengthening of the US dollar in the second quarter of 2009 vis-à-vis the
euro, and despite the increase in licence fee and other comparative revenues.

    Consolidated R&D costs, net of tax credits and grants, were $12.1 for the
three-month period ended June 30, 2009 compared to $17.3 million for the same
period in 2008. The comparative decrease in net R&D costs is largely
attributable to a lower volume of expenses incurred in connection with the
continued advancement of the Company's Phase 3 program for its lead compound,
cetrorelix, in BPH, as well as to euro to US dollar exchange rate
fluctuations, as discussed above.

    Consolidated selling, general and administrative ("SG&A") expenses were
$3.1 million for the three-month period ended June 30, 2009, compared to $6.6
million for the same period in 2008. This decrease is related to comparative
euro to US dollar exchange rate fluctuations, the absence in 2009 of certain
non-recurring corporate expenses related to organizational changes, including
severance costs, which had been incurred in the second quarter of 2008, and to
continuing cost-saving measures that were implemented beginning in the second
quarter of 2008.

    Consolidated net loss for the three-month period ended June 30, 2009 was
$13.1 million, or $0.24 per basic and diluted share, compared to $20.6
million, or $0.39 per basic and diluted share, for the same period in 2008.
This decrease is mainly related to lower comparative R&D and SG&A expenses,
partially offset by lower comparative revenues, as discussed above.

    Consolidated cash, cash equivalents and short-term investments were $57.3
million as at June 30, 2009.


    Management will be hosting a conference call for the investment community
beginning at 10:00 a.m. Eastern Time today, Tuesday, August 11, 2009, to
discuss second quarter 2009 results. Individuals interested in participating
in the live conference call by telephone may dial 800-588-4942, 416-644-3426,
or 514-807-8791, or may listen through the Internet at A
replay will be available on the Company's website for 30 days following the
live event.

    About AEterna Zentaris Inc.

    AEterna Zentaris Inc. is a global biopharmaceutical company focused on
endocrine therapy and oncology, with proven expertise in drug discovery,
development and commercialization. News releases and additional information
are available at

    Forward-Looking Statements

    This press release contains forward-looking statements made pursuant to
the safe harbor provisions of the U.S. Securities Litigation Reform Act of
1995. Forward-looking statements involve known and unknown risks and
uncertainties, which could cause the Company's actual results to differ
materially from those in the forward-looking statements. Such risks and
uncertainties include, among others, the availability of funds and resources
to pursue R&D projects, the successful and timely completion of clinical
studies, the ability of the Company to take advantage of business
opportunities in the pharmaceutical industry, uncertainties related to the
regulatory process and general changes in economic conditions. Investors
should consult the Company's quarterly and annual filings with the Canadian
and U.S. securities commissions for additional information on risks and
uncertainties relating to the forward-looking statements. Investors are
cautioned not to rely on these forward-looking statements. The Company does
not undertake to update these forward-looking statements. We disclaim any
obligation to update any such factors or to publicly announce the result of
any revisions to any of the forward-looking statements contained herein to
reflect future results, events or developments except if we are required by a
governmental authority or applicable law.

    Attachment: Financial summary

    Quarterly Interim Consolidated Statements of Loss (unaudited)

                                  Three months ended        Six months ended
                                        June 30,                June 30,
    (in thousands)                  2009        2008        2009        2008
                                       $           $           $           $
    Sales and royalties            5,427       8,250      10,398      16,192
    License fees and other         2,952       2,207       4,092       4,013
                                   8,379      10,457      14,490      20,205
    Operating expenses
    Cost of sales                  4,545       4,758       8,239       9,362
    Research and development
     costs, net of tax credits
     and grants                   12,076      17,345      23,513      31,034
    Selling, general and
     administrative                3,102       6,606       6,656      11,010
    Depreciation and
      Property, plant and
       equipment                     331         397         642         766
      Intangible assets              563         876       1,120       1,716
                                  20,617      29,982      40,170      53,888
    Loss from operations         (12,238)    (19,525)    (25,680)    (33,683)
    Other income (expenses)
    Interest income                  118         311         274         588
    Interest expense                   -         (53)         (2)        (68)
    Foreign exchange
     (loss) gain                    (960)       (502)        (60)      1,753
    Loss on disposal of
     long-lived assets
     held for sale                     -        (810)          -         (35)
                                    (842)     (1,054)        212       2,238
    Net loss for the period      (13,080)    (20,579)    (25,468)    (31,445)

    Net loss per share
    Basic and diluted              (0.24)      (0.39)      (0.48)      (0.59)
    Weighted average
     number of shares
    Basic and diluted         53,655,087  53,187,470  53,422,571  53,187,470

    Interim Consolidated Balance Sheet Information (unaudited)
                                                         As at         As at
                                                       June 30,  December 31,
    (in thousands)                                        2009          2008
                                                             $             $

    Cash and cash equivalents                           56,817        49,226
    Short-term investments                                 518           493
    Accounts receivable and other current assets        13,420        12,005
    Property, plant and equipment                        6,387         6,682
    Other long-term assets                              40,298        39,936
    Total assets                                       117,440       108,342

    Accounts payable and other current liabilities      27,006        22,121
    Current portion of long-term payable                    52            49
    Long-term payable                                      155           172
    Non-financial long-term liabilities                 86,858        64,525
    Total liabilities                                  114,071        86,867
    Shareholders' equity                                 3,369        21,475
    Total liabilities and shareholders' equity         117,440       108,342

For further information:

For further information: Investor Relations: Ginette Vallières, Investor
Relations Coordinator, (418) 652-8525, ext. 265,; Media
Relations: Paul Burroughs, Director of Communications, (418) 652-8525, ext.

Organization Profile

Aeterna Zentaris Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890